Dr. Jorge Llibre is a Washington University neurologist that researches Alzheimer’s. He says research shows the Hispanic community is two times more likely to develop Alzheimer’s or dementia than non-Hispanics.
Author: Ronald
Risk of Alzheimer’s dementia may be predicted with help of new tool (Links to an external site)
Using demographic information, brain imaging test results and genetic biomarkers, researchers at Washington University School of Medicine in St. Louis have developed an algorithm that can help provide people who volunteer for studies of aging with information about the risk each faces of developing dementia due to Alzheimer’s disease.
With early Alzheimer’s in the family, these sisters decided to test for the gene (Links to an external site)
New Alzheimer’s diagnoses more common among seniors who have had Covid-19, study finds (Links to an external site)
A recent study of more than 6 million people 65 and older found that seniors who had Covid-19 had a substantially higher risk of being diagnosed with Alzheimer’s disease within a year.
Study points to new approach to clearing toxic waste from brain (Links to an external site)
Researchers at Washington University School of Medicine in St. Louis have found a new druggable pathway that potentially could be used to help prevent Alzheimer’s dementia.
Preclinical Alzheimer’s disease biomarkers accurately predict cognitive and neuropathological outcomes (Links to an external site)
The detection of preclinical Alzheimer disease biomarkers is strongly predictive of future cognitive impairment and accurately predicts presence of Alzheimer disease neuropathology at autopsy.
Dr. John C. Morris discusses biomarkers. (Links to an external site)
Dr. John C. Morris, MD, FAAN shares what he learned as the guest editor of the June 2022 Continuum issue on Dementia which includes biomarkers.
How deep sleep keeps our brains intact (Links to an external site)
How St. Louis researchers are seeking ways to combat Alzheimer’s and dementia (Links to an external site)
2022 State of the Knight ADRC (Links to an external site)
Access this year’s and an archive of past Lectures by clicking the link above.
2022 Participants’ Meeting (Links to an external site)
See this year’s Participants’ Meeting. Click the red text above and then the “Start Watching” button.
Race of people given Alzheimer’s blood tests may affect interpretation of results (Links to an external site)
Three experimental blood tests used to identify people in early stages of Alzheimer’s disease perform differently in Black individuals compared to white individuals, according to a new study from Washington University School of Medicine in St. Louis.
Risky driving behaviors increase as common sleep disorder worsens (Links to an external site)
Diagnosing, treating sleep apnea may make driving safer for older adults
New strategy reduces brain damage in Alzheimer’s and related disorders, in mice (Links to an external site)
A study by researchers at Washington University School of Medicine in St. Louis has shown that targeting astrocytes — an inflammatory cell in the brain — reduces tau-related brain damage and inflammation in mice.
New blood test may accurately detect Alzheimer’s disease (Links to an external site)
Now, a blood test developed by researchers at Washington University School of Medicine, St. Louis, has shown promising results in detecting the early signs of AD.
ANA Investigates: A Podcast Series (Links to an external site)
On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia?
Could drugs prevent Alzheimer’s? These trials aim to find out (Links to an external site)
Could drugs prevent Alzheimer’s? These trials aim to find out
Damage early in Alzheimer’s disease ID’d via novel MRI approach (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
Blood test can predict presence of beta-amyloid in the brain, new study finds (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
How a hyperactive cell in the brain might trigger Alzheimer’s disease (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
Racial equity in Alzheimer’s research focus of $7 million in grants (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
“In Our Right Minds” Documentary (Links to an external site)
View the webinar screening and panel discussion of Renee Chenault-Fattah’s documentary on how dementias affect communities of color.
Annual Norman R. Seay Lecture (Links to an external site)
Watch the 2021 Lecture by Dr. Jeffrey McClean II entitled “Organizational Equity, Diversity, and Inclusion: Driving Forces and Stumbling Blocks”
State of the Knight ADRC Lecture (Links to an external site)
View Dr. John C. Morris give the annual State of the Knight ADRC Lecture for 2021.
New Alzheimer’s treatment targets identified (Links to an external site)
A research team at Washington University School of Medicine in St. Louis has identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that have therapeutic potential against these targets.
We May Be Getting Closer to an Alzheimer’s Vaccine (Links to an external site)
A new study shows safety and potential benefit for patients with mild disease. Axon’s experimental vaccine AADVac1—currently the most clinically advanced tau therapy in development—aims to do exactly that. Its goal is to activate our bodies’ defense system to clear out free-floating tau proteins in our brains before they can form harmful tangles that accumulate inside nerve […]
Blood tests could help screen anticipated flood of patients seeking new Alzheimer’s drug (Links to an external site)
When the U.S. government approved the Alzheimer’s disease drug aducanumab last month despite shaky evidence of clinical benefits, Suzanne Schindler saw an immediate consequence: “We’re going to have to do a lot more biomarker testing.” Schindler, a neurologist at the Washington University School of Medicine in St. Louis, expects many patients with memory problems will […]
Investigational Alzheimer’s drug improves biomarkers of the disease (Links to an external site)
An investigational Alzheimer’s drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU). These results led the trial leaders to offer the drug, […]